Clinical trial NCT03775161: V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
Official title: A First in Human Multi-center, Open Label, Prospective Study to Evaluate the Safety, Usability and Performance of the V-LAP™ System
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Heart Failure
Lead sponsor: Vectorious Medical Technologies Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Horizon 2020 - European Commission
First posted: 2018-12-13
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.

Detailed description: The trial is designed to demonstrate that the V-LAP™ implant can be positioned in the interatrial septum, and that Sensor pressure measurements correlate to standardized methods of intra-cardiac pressure measurements post-sensor implant and at the 3 month follow up visit. Safety will be monitored by the occurrence of adverse events throughout the trial.

Eligibility criteria: Inclusion Criteria:

1. Ischemic or non-ischemic cardiomyopathy and documented heart failure for at least 6 months.
2. ACC/AHA Stage C, NYHA Class III or ambulatory Class IV HF documented at Baseline Visit.
3. Receiving maximally tolerated medical therapy for heart failure as indicated per ACC/AHA or ESC Heart Failure Guidelines (guideline-directed medical therapy or GDMT), such as diuretic, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), beta-blocker (BB), and mineralocorticoid receptor blocker (MRB) for at least 3 months prior to the Baseline visit.
4. Receiving rhythm management device therapy as recommended by the ACC/AHA or ESC Guidelines. Specifically: cardiac resynchronization therapy (CRT) should be implanted for at least 90 days prior to enrollment; an implanted cardioverter-defibrillator (ICD) or a pacemaker should be implanted at least 30 days prior to enrollment. If subject is clinically contraindicated for these therapies this criterion may be waived.
5. Have a minimum of one (1) prior hospital admission within the last 12-months for acute worsening of HF associated with signs/symptoms of congestion of at least one (1) calendar date change duration requiring treatment with an intravenous diuretic. If CRT device previously implanted, the heart failure hospitalization must be ≥ 30 days after CRT implantation. Alternatively, if patients have not had a HF hospitalization within the prior 12-months, they must have a corrected\* elevated Brain Natriuretic Peptide (BNP) level of at least 300pg/ml or an N-terminal pro-BNP (NT-proBNP) level of at least 1,500pg/ml, according to local measurement, within 30-days of the Baseline Visit. \*Thresholds for NT-proBNP will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 20 kg/m2, If patient is on ARNI, NT-proBNP should be used exclusively.
6. Provide informed consent for study participation and be willing and able to comply with the required tests, treatment instructions and follow-up visits.

   -

Exclusion Criteria:

1. Age \<18 or \>85 years old.
2. Patients who are NYHA class IV not ambulatory and ACC stage D.
3. Patients with evidence/history of an intra-cardiac thrombus or history of stroke, transient ischemic attack, systemic or pulmonary thromboembolism, deep vein thrombosis (DVT), within the last 6 months.
4. Patients with a resting systolic blood pressure \<90 or \>180 mmHg and/ or Severe pulmonary hypertension with a pulmonary artery systolic pressure of ≥70 mm/Hg on screening baseline echocardiogram.
5. Left ventricular end-diastolic diameter (LVEDD) \> 8cm.
6. Have an atrial septal defect or patent foramen ovale with more than trace shunting on color Doppler or intravenous bubble study or surgical or interventional correction of congenital heart disease involving atrial septum including placement of a PFO or ASD closure device and have a hypermobile septum or a septal aneurysm
7. Patients with untreated severe valve lesions, which are indicated for surgical or percutaneous intervention, severe regurgitant (grade 4+) valve lesions, active valvular vegetations, atrial myxoma, hypertrophic cardiomyopathy with significant resting or provoked subaortic gradient, acute myocarditis, tamponade, or large pericardial effusion, constrictive pericarditis, infiltrative cardiomyopathy (including cardiac sarcoidosis, amyloidosis, and hemochromatosis), or congenital heart disease, as cause of HF.
8. Uncontrolled tachyarrhythmia or bradycardia (heart rate \<45).
9. Intractable HF with resting symptoms despite maximal medical therapy (ACC/AHA HF Stage D), including patients receiving continuous or intermittent outpatient IV vasoactive medications (e.g., IV inotropes, IV vasodilators), patients treated with a ventricular assist device (VAD).
10. Intolerant to diuretics, ACEI and ARB and beta-blocker medical therapy for patients classified as HFrEF (EF ≤40%).
11. The presence of an acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), rhythm management system revision, lead extraction, or cardiac or other major surgery within the preceding 90 days.
12. Patients not eligible for emergency open-heart, thoracic or vascular surgery.
13. Women of childbearing age
14. Patients with a life expectancy that is shorter than 12 months, or those who have received a cardiac transplant or are listed for cardiac transplantation and likely to be transplanted within 12 months.
15. Have coagulopathy or uninterruptible anticoagulation therapy or contraindication for all of the forms of antiplatelet/anticoagulant treatments anticipated in the protocol
16. Have an estimated glomerular filtration rate \<25 ml/min/1.73 m2 by the MDRD method or on dialysis.
17. Hepatic impairment with at least one liver Function Test (transaminases, total bilirubin, or alkaline phosphatase) ≥ 3 times upper limit of normal.
18. Gastrointestinal bleeding in the last 6 months
19. Have severe chronic pulmonary disease requiring continuous home oxygen, chronic oral steroid therapy, hospitalization for exacerbation during prior 6 months, or has severe obstructive physiology on PFTs (FEV1/FVC \<0.70 and FEV1 \< 50% normal).
20. Patients who have an active infection requiring systemic antibiotics or an elevated white blood count (above the local laboratory reference ranges)
21. Have a history of active drug addiction, active alcohol abuse, or psychiatric hospital admission for psychosis within the prior 2 years.
22. Are currently participating in a clinical investigation that includes an active treatment arm.
23. Subject otherwise not appropriate for study as determined by the investigator. The reasons must be documented.
24. Patients contraindicated for trans-septal puncture, TEE or ICE.

    Intra Procedural Exclusion Criteria:

    (Intra Procedural Exclusion Criteria will be determined immediately after intracardiac echocardiography or transesophageal echocardiography determination of left atrial anatomy and just before trans-septal puncture)
25. Anatomical anomaly on TEE or ICE that precludes implantation of the V-LAPIM across the interatrial septum (Fossa Ovalis) including: Septal thickness at fossa \> 5 mm, FO Dimension \<16mm, ASD or PFO with more than a trace amount of shunting, Intra- cardiac thrombus felt to be acute and not present on prior exams and Abnormal septum, e.g. a hypermobile septum or a septal aneurysm.
26. Inadequate vascular access for implantation of V-LAPIM or are unable to tolerate an RHC.
27. Hemodynamic at time of Index Procedure including: Severe pulmonary hypertension defined as PASP\>70 mmHg or PVR \>4.0 Woods Units (mmHg L-1 min-1); Resting systolic Blood Pressure \<90 or \>180 mmHg, not corrected with IV fluid administration or vasodilators, respectively.

Primary outcomes:
measure: Usability of the Delivery System
timeFrame: Intraoperative (Implantation)
measure: Safety Endpoint: Study (Device and/ or system) related Major Adverse Cardiac and Neurological Events (MACNE)
timeFrame: Up to three months post-procedure
Secondary outcomes:
measure: Performance communication
timeFrame: Up to three months post-procedure
measure: Performance accuracy
timeFrame: At index (baseline) and at three months
measure: Usability Assessment
timeFrame: Up to 24 months post procedure
Other outcomes:
measure: NYHA functional class
timeFrame: Up to 24 months post procedure
measure: KCCQ score
timeFrame: Up to 24 months post procedure
measure: Heart failure hospitalization rate
timeFrame: Up to 60 months post procedure
Locations:
city: Frankfurt
country: Germany
facility: CardioVasculäres Centrum Frankfurt
city: Florence
country: Italy
facility: Careggi University Hospital Trust
Study officials:
affiliation: Director and Founder of CardioVasculäres Centrum Frankfurt
name: Horst Sievert, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Florence and Careggi University Hospital
name: Carlo Di Mario, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Consultant Cardiologist, Queen Elizabeth Hospital
name: Francisco Leyva, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: D Ancona G, Murero M, Feickert S, Kaplan H, Oner A, Ortak J, Ince H. Implantation of an Innovative Intracardiac Microcomputer System for Web-Based Real-Time Monitoring of Heart Failure: Usability and Patients' Attitudes. JMIR Cardio. 2021 Apr 21;5(1):e21055. doi: 10.2196/21055.
citation: D'Amario D, Restivo A, Canonico F, Rodolico D, Mattia G, Francesco B, Vergallo R, Trani C, Aspromonte N, Crea F. Experience of remote cardiac care during the COVID-19 pandemic: the V-LAP device in advanced heart failure. Eur J Heart Fail. 2020 Jun;22(6):1050-1052. doi: 10.1002/ejhf.1900. Epub 2020 Jun 26. No abstract available.